SiNtx Technologies Inc (SINT)

[boston745]

That is not what i said, which is why you are correct in what you describe as being "wrong" (disinformation tactic to alter what was said). I said your posts continue to support Anson's efforts to distort and thus short. I say that because your posts continue to distort facts to fit a very negative narrative. You claimed the only successful thing management has done is ensure funding for their salaries and bonuses. That is not truthful statement as we have discussed before. Sonny has been very successful in R&D and patenting Sintx tech to date increasing addressable markets from $64bn to about $300bn as shown in Section 3 of this post. Thus your statement is a distortion of the facts and thus your post supports Ansons agenda to distort the facts for those that short.

Wrong again. The fact that Anson and I share in the strong belief that Sint is a loser doesn't make me aid in anything he does.

I do not make it "appear" that this was mainly done in the past, thats a fact. Accumulated deficit was $144m March 2014 just as the company went public; around 140m to close 2013, hard to say exact deficit upon going public. Current deficit is 274m; meaning 10-14m more was accumulated pre-IPO. Thus while Sintx was private its accumulated deficit is larger than since its been public and thus its paid in capital must be larger as well; currently at 283m and looks like it was about 149m before IPO. As you can see this will only remain true for another year or two unless they can increase revenue to the point deficit is not accumulated any longer.
All companies require investment in their early years. This is esspecially true for Biotech and Medtech companies as they require alot of investment. When Confor went private, did they not have an accumulated deficit of over $500m? This while only having an addressable market of like 23+bn compared to Sintx 300bn. Confor's product is barely different than current implants on the market while Sintx Si3n4 is very different and superior to the main the materials used in the ortho industry currently as shown in Section 4 of this post.

Make it appear to others that this was a thing MAINLY DONE in the past, and that OTHER companies do as well

Yes, you mentioned the R&D stage, but you don't ever mention that they NEVER come out of it

Do i never mention they have yet to come out of R&D stage? Because im pretty sure i indicated exactly that in the post you just replied to. I have also complaied about the slow pace here, a fact worsened by the fact that SINT is so badly undervalued reducing funds they can raise leading to things like current cutbacks in personnel. Also you're stating never like they can never come out of the R&D stage. They could come out of it and have several larger partners that could help them do so. When that'll happen, i wish i knew!

My Post:

As in they are still developing their core IP and have not commercialized the bulk of its IP to date.

One more thing. I do get things wrong and do correct myself most of the time when i do. Like the $2.5m certain R&D payment Zimmer paid Q2 2017 and the fact that Dr Bal's investment company loaned that amount to Sintx Q3'17. I believed, and still do, the payment is related to IP connected to the testing of Sintx and Zimmer Biomet IP but ive had to revise it many times because i do not have all the details. The base concept is Zimmer Biomet paid an entitiy $2.5m. That entity then invested those funds with Dr Bal's investment company which was then loaned to Sintx. It was a clever way to get funds to Sintx from Zimmer using a pre-established agreement. The loan was used a birdge loan to help protect Sintx core IP once the Hercules loan was paid off. Hercules loan had first rights to Sintx core IP with Dr Bal's investment company having second place rights. Once Hercules loan was paid off, the investment company had first rights to Sintx IP until CTL closed. Now CTL has first rights to acquire Sintx IP working as a Crown Jewel defense. CTL rights to Sintx core IP expires in 2028 unless a new contract is signed.

https://www.sec.gov/cgi-bin/viewer?action=view&cik=1269026&accession_number=0001564590-14-002254&xbrl_type=v#

========================================

Section 2 - A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

========================================

Section 3 Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn

Total = $310.77bn

========================================

Section 4 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.

https://www.mdpi.com/2571-6131/4/2/16/htm